Clinical Trial · NCT07602569

A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT

Overview

Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Contacts

HAO PENG (CONTACT)

1194171163@qq.com

0086-13544443827

Rusen Zhang (CONTACT)

zhangrusen2015@163.com

0086-13642328295

ClinicalTrials.gov

NCT07602569

Drug / Compound

FGln

Isotope(s):

Target(s):

Glutaminolytic Activity

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives)
Patients without other tumor history
Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy

Exclusion

other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial
patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations.
those who have undergone gastrointestinal barium meal examination within one week;